Role of dynamic perfusion magnetic resonance imaging in patients with local advanced rectal cancer

Table 1 Differences in terms of perfusion parameters in the healthy rectal wall and the tumor tissue, determines through the dynamic contrast enhanced magnetic resonance imaging study for staging rectal cancer (MR1)

DCE-MRI parameters	Healthy rectal wall	Rectal tumor	P value
RAE (mean ± SD)	57.5 ± 41.5	100 ± 38	0.005
RVE (mean ± SD)	75.5 ± 43	119.5 ± 26.5	0.005
RLE (mean ± SD)	82 ± 38.5	114 ± 22.5	0.005
ME (mean ± SD)	807 ± 227.5	1143.5 ± 348	0.004
TTP (mean ± SD)	217 ± 79	185 ± 41	0.040
AUC (mean ± SD)	114388.5 ± 46237.5	186197 ± 41042.5	0.005

DCE-MRI: Dynamic-contrast enhanced magnetic resonance imaging; RAE: Relative arterial enhancement; RVE: Relative venous enhancement; RLE: Relative late enhancement; ME: Maximum enhancement; TTP: Time to peak; AUC: Area under the curve.

Table 2 Differences in terms of perfusion parameters between responders and non-responders, in the healthy rectal wall, determines through a dynamic contrast enhanced magnetic resonance imaging study during staging (MR1) and restaging (MR2) of rectal cancer after chemo-radiotherapy

DCE-MRI parameters	Responders			Non-responders
	MR1	MR2	P value	MR1	MR2	P value
RAE (mean ± SD)	62 ± 33	51 ± 8	0.77	53 ± 50	63 ± 33	0.47
RVE (mean ± SD)	70 ± 40	60 ± 14	0.73	81 ± 46	69 ± 42	0.68
RLE (mean ± SD)	72 ± 35	76 ± 10	0.49	92 ± 42	63 ± 52	0.61
ME (mean ± SD)	662 ± 98	882 ± 251	0.11	952 ± 357	847 ± 358	0.87
TTP (mean ± SD)	230 ± 61	223 ± 32	0.64	204 ± 97	151 ± 56	0.05
AUC (mean ± SD)	120261 ± 46709	114347 ± 32930	0.74	108516 ± 45766	114187 ± 28584	0.99

DCE-MRI: Dynamic-contrast enhanced magnetic resonance imaging; RAE: Relative arterial enhancement; RVE: Relative venous enhancement; RLE: Relative late enhancement; ME: Maximum enhancement; TTP: Time to peak; AUC: Area under the curve.

Table 3 Differences in terms of perfusion parameters between responders and non-responders, in the tumor tissue, determines through a dynamic contrast enhanced magnetic resonance imaging study for staging rectal cancer (MR1)

DCE-MRI Parameters	Responders	Non-responders	P value
RAE (mean ± SD)	115 ± 21	85 ± 55	0.27
RVE (mean ± SD)	119 ± 21	120 ± 32	0.94
RLE (mean ± SD)	111 ± 14	117 ± 31	0.72
ME (mean ± SD)	1060 ± 325	1227 ± 371	0.52
TTP (mean ± SD)	196 ± 12	175 ± 70	0.51
AUC (mean ± SD)	203361 ± 14347	169033 ± 67738	0.28

DCE-MRI: Dynamic-contrast enhanced magnetic resonance imaging; RAE: Relative arterial enhancement; RVE: Relative venous enhancement; RLE: Relative late enhancement; ME: Maximum enhancement; TTP: Time to peak; AUC: Area under the curve.

Table 4 Differences in terms of perfusion parameters between responders and non-responders in the tumor tissue, determines through a dynamic contrast enhanced magnetic resonance imaging study for rectal cancer restaging (MR2) after chemo-radiotherapy

DCE-MRI parameters	Responders	Non-responders	P value
RAE (mean ± SD)	54 ± 20	129 ± 45	0.02
RVE (mean ± SD)	73 ± 24	154 ± 39	< 0.05
RLE (mean ± SD)	82 ± 29	164 ± 35	< 0.05
ME (mean ± SD)	904 ± 429	1714 ± 427	0.03
TTP (mean ± SD)	218 ± 18	196 ± 23	0.15
AUC (mean ± SD)	120894 ± 50495	258022 ± 86469	0.02

DCE-MRI: Dynamic-contrast enhanced magnetic resonance imaging; RAE: Relative arterial enhancement; RVE: Relative venous enhancement; RLE: Relative late enhancement; ME: Maximum enhancement; TTP: Time to peak; AUC: Area under the curve.